NxStage Medical Inc. (NASDAQ:NXTM) Director Daniel A. Giannini sold 6,449 shares of the company’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $25.96, for a total value of $167,416.04. Following the sale, the director now owns 63,193 shares in the company, valued at approximately $1,640,490.28. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) traded down 5.19% during mid-day trading on Tuesday, hitting $24.49. The stock had a trading volume of 676,148 shares. NxStage Medical Inc. has a 52-week low of $13.49 and a 52-week high of $26.83. The firm’s market cap is $1.59 billion. The stock’s 50-day moving average price is $24.30 and its 200-day moving average price is $22.50.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Several brokerages recently commented on NXTM. BTIG Research restated a “buy” rating and set a $29.00 target price on shares of NxStage Medical in a research report on Sunday, August 7th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price target on shares of NxStage Medical in a report on Thursday, November 3rd. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 price target on the stock in a report on Thursday, November 3rd. Northland Securities set a $25.00 price target on NxStage Medical and gave the stock a “buy” rating in a report on Thursday, September 15th. Finally, Jefferies Group increased their price target on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. NxStage Medical has an average rating of “Buy” and an average target price of $25.67.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTM. Acrospire Investment Management LLC increased its position in NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock valued at $101,000 after buying an additional 4,378 shares in the last quarter. Pacad Investment Ltd. bought a new position in NxStage Medical during the second quarter valued at approximately $111,000. BNP Paribas Arbitrage SA increased its position in NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock valued at $120,000 after buying an additional 2,026 shares in the last quarter. BlackRock Inc. increased its position in NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock valued at $136,000 after buying an additional 2,116 shares in the last quarter. Finally, Cutler Group LP increased its position in NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock valued at $155,000 after buying an additional 1,583 shares in the last quarter. Hedge funds and other institutional investors own 98.86% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “NxStage Medical Inc. (NXTM) Director Sells $167,416.04 in Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/22/nxstage-medical-inc-nxtm-director-sells-167416-04-in-stock.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.